Americana Partners LLC Takes Position in Boston Scientific Corporation $BSX

Americana Partners LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,079 shares of the medical equipment provider’s stock, valued at approximately $691,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter valued at about $26,000. Sound Income Strategies LLC increased its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. acquired a new position in shares of Boston Scientific during the 3rd quarter worth $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Finally, Kilter Group LLC acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $30,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Robert W. Baird increased their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Barclays upped their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $123.89.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.6%

Shares of NYSE:BSX opened at $91.74 on Thursday. The company has a market cap of $136.00 billion, a price-to-earnings ratio of 49.06, a PEG ratio of 1.61 and a beta of 0.67. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The firm has a fifty day moving average price of $96.17 and a two-hundred day moving average price of $100.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.